Crustacean Shell Collagen
Crustacean shell collagen is a marine-derived collagen source extracted from the exoskeletons of shrimp, crab, and lobster, where it is structurally associated with chitin polysaccharides. Current research is limited to isolation and extraction methodology, with no clinical trials establishing therapeutic efficacy in humans.

Origin & History
Crustacean shell collagen refers to collagen potentially extracted from the shells of marine crustaceans like shrimp, crabs, and lobsters, though research indicates chitin (a structural polysaccharide) is the dominant component extracted from shells rather than collagen itself. Industrial extraction involves deproteinization with alkaline treatment and demineralization with acid treatment, yielding primarily chitin powder rather than collagen protein.
Historical & Cultural Context
No historical or traditional medicinal uses of crustacean shell collagen in any traditional medicine systems (including Ayurveda or TCM) were documented. Current applications focus on modern industrial extraction from seafood waste.
Health Benefits
• No clinical health benefits documented - research focuses solely on extraction methods rather than therapeutic effects • No human trials identified examining biomedical applications • No efficacy data available from controlled studies • No meta-analyses or systematic reviews found • Current evidence limited to industrial extraction processes only
How It Works
Crustacean shell collagen is structurally bound to chitin, a β-1,4-linked N-acetylglucosamine polymer, forming a composite matrix within the exoskeleton. Upon hydrolysis, the resulting collagen peptides theoretically contain hydroxyproline-rich tripeptide sequences (Gly-X-Y) that may interact with fibroblast receptors to stimulate extracellular matrix synthesis, similar to other marine collagens. However, no peer-reviewed studies have confirmed receptor-level mechanisms or downstream signaling pathways such as TGF-β activation or MMP inhibition specifically for crustacean shell-derived collagen.
Scientific Research
No human clinical trials, randomized controlled trials, or meta-analyses specifically on crustacean shell collagen were identified in the available research. The existing literature focuses exclusively on extraction methodologies without any PMIDs available for clinical contexts.
Clinical Summary
No human clinical trials have been conducted examining crustacean shell collagen as a therapeutic supplement, leaving a complete absence of controlled efficacy data. Available literature is restricted to materials science and biochemistry studies focused on extraction protocols, such as acid-solubilization and pepsin-assisted methods, rather than biomedical outcomes. No meta-analyses, systematic reviews, or observational studies have examined dosage, bioavailability, or health endpoints in human populations. The evidence base is currently insufficient to support any clinical recommendations.
Nutritional Profile
Crustacean shell collagen is a fibrous structural protein (primarily Type I collagen) extracted from the exoskeletons and shell matrices of shrimp, crab, lobster, and other crustaceans. It is not a conventional dietary food but rather an industrial/research-grade protein isolate. **Protein content:** Typically 85–95% protein (dry weight basis) once purified, composed predominantly of repeating Gly-X-Y tripeptide sequences where X is frequently proline (~12–14% of amino acid residues) and Y is frequently hydroxyproline (~10–12%). **Key amino acid profile (approximate, per 100 g dry collagen):** Glycine ~25–33 g, proline ~10–14 g, hydroxyproline ~8–12 g, alanine ~8–10 g, glutamic acid ~7–10 g, arginine ~5–8 g. Notably low in essential amino acids tryptophan (<0.5 g), methionine (~1 g), and histidine (~1 g), making it an incomplete protein by nutritional standards. **Micronutrients:** Residual mineral content from shell origin includes calcium (50–500 mg/100 g depending on purification), phosphorus (20–100 mg/100 g), magnesium (10–50 mg/100 g), and trace zinc and selenium. Chitin and chitosan contamination is common in less-purified extracts (up to 5–15% w/w), which contributes insoluble fiber-like polysaccharide content. **Bioactive compounds:** Hydroxyproline and hydroxylysine are collagen-specific amino acids with potential roles as bioactive peptides when hydrolyzed (molecular weight of hydrolysates typically 1–10 kDa). Astaxanthin and other carotenoid residues may be present in trace amounts (<0.01–0.1 mg/100 g) if co-extracted with pigmented shell material. **Bioavailability notes:** Native crustacean shell collagen has very low digestibility due to its triple-helix tertiary structure and extensive cross-linking; enzymatic hydrolysis (using pepsin, trypsin, or alcalase) significantly improves bioavailability and intestinal absorption of resulting peptides. Collagen from crustacean shells is generally considered lower yield and lower purity compared to fish skin or bovine sources due to heavy mineralization (CaCO₃) and chitin interference in the shell matrix. Fat content is negligible (<1%), and carbohydrate content is negligible unless chitin residues are included. No significant vitamin content is inherent to the collagen fraction itself.
Preparation & Dosage
No clinically studied dosage ranges, standardized forms, or dosing protocols have been established for crustacean shell collagen. Consult a healthcare provider before starting any new supplement.
Synergy & Pairings
No synergistic ingredients identified in research
Safety & Interactions
Individuals with shellfish allergies face a significant contraindication, as crustacean shell collagen retains allergenic proteins from shrimp, crab, or lobster exoskeletons that can trigger IgE-mediated hypersensitivity reactions. No formal drug interaction studies exist, though the associated chitin component may theoretically affect absorption of fat-soluble medications if consumed in large quantities due to its gel-forming properties. Pregnancy and lactation safety has not been evaluated in any published study, making use inadvisable in these populations without medical supervision. General side effects have not been systematically characterized due to the absence of clinical trials.